NASDAQ:ERYP ERYTECH Pharma (ERYP) Stock Price, News & Analysis → A new way to collect income from stocks (From DTI) (Ad) Free ERYP Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$3.10▼$3.1050-Day Range$4.19▼$5.0852-Week Range$0.30▼$1.47VolumeN/AAverage Volume93,510 shsMarket Capitalization$105.77 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsHeadlinesSocial MediaStock AnalysisCompetitorsHeadlinesSocial Media Get ERYTECH Pharma alerts: Email Address Ad DTIA new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. About ERYTECH Pharma Stock (NASDAQ:ERYP)ERYTECH Pharma S.A., a biopharmaceutical company, focus on development of red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. ERYTECH Pharma S.A. was incorporated in 2004 and is headquartered in Lyon, France.Read More Ad DTIA new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. ERYP Stock News HeadlinesFebruary 21, 2024 | finanznachrichten.dePhaxiam Therapeutics S.A.: PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital MarketJanuary 19, 2024 | morningstar.comRoyalty Pharma PLC Class A RPRXApril 25, 2024 | DTI (Ad)What is the 72-Hour Profit Surge?One of the most overlooked opportunities in the stock market is the 72-Hour Profit Surge... A short period of time where we can bet on a stock that is ALREADY “winning.” Let me give you a perfect example of how the Surge worked with Ross Stores. Back on November 16th, a little move was made that sent their stock soaring… The next day, my system would have alerted me that Ross Stores had entered the 72-Hour Profit Surge…June 28, 2023 | finanznachrichten.deErytech Pharma S.A.: Phaxiam Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PHXMJune 28, 2023 | finance.yahoo.comPhaxiam Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PHXMJune 27, 2023 | finance.yahoo.comMonthly information related to total number of voting rights and shares composing the share capital - June 26, 2023June 26, 2023 | finance.yahoo.comERYTECH and PHERECYDES announce merger and name change to PHAXIAM TherapeuticsJune 23, 2023 | finance.yahoo.comERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder’s Meeting held on June 23, 2023April 25, 2024 | DTI (Ad)What is the 72-Hour Profit Surge?One of the most overlooked opportunities in the stock market is the 72-Hour Profit Surge... A short period of time where we can bet on a stock that is ALREADY “winning.” Let me give you a perfect example of how the Surge worked with Ross Stores. Back on November 16th, a little move was made that sent their stock soaring… The next day, my system would have alerted me that Ross Stores had entered the 72-Hour Profit Surge…June 20, 2023 | finanznachrichten.deErytech Pharma S.A.: ERYTECH announces that Akkadian is continuing its attempt at destabilization with the filing of a new lawsuitJune 15, 2023 | msn.comTech, Pharma Stocks Lead European Equities Higher in Thursday TradingJune 14, 2023 | finance.yahoo.comERYTECH announces that the Commercial Court has rejected Akkadian's request to postpone the vote on the merger with Pherecydes PharmaJune 13, 2023 | benzinga.comErytech's Battle With Activist Investor Echoes As Pherecydes Pharma Merger Vote Comes CloserJune 13, 2023 | finance.yahoo.comMonthly information related to total number of voting rights and shares composing the share capital _May 31, 2023June 12, 2023 | finanznachrichten.deErytech Pharma S.A.: ERYTECH Responds to Akkadian's DisinformationJune 12, 2023 | finance.yahoo.comERYTECH Responds to Akkadian’s DisinformationJune 5, 2023 | finanznachrichten.deErytech Pharma S.A.: ERYTECH announces that Akkadian has initiated proceedings to postpone the vote on the merger with PherecydesJune 5, 2023 | finance.yahoo.comERYTECH announces that Akkadian has initiated proceedings to postpone the vote on the merger with PherecydesMay 24, 2023 | finance.yahoo.comERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 23, 2023May 24, 2023 | msn.comPharma Stocks Lead European Equities Sharply Lower in Wednesday TradingMay 23, 2023 | businesswire.comPHERECYDES Announces the Availability of the Exemption Document Relating to the Proposed Combination With Erytech PharmaMay 23, 2023 | finance.yahoo.comERYTECH announces the availability of the exemption document relating to the proposed combination with PherecydesMay 23, 2023 | msn.comPharma Stocks Lead European Equities Modestly Lower in Tuesday TradingMay 19, 2023 | msn.comEuropean Equities Rise in Friday Trading, Poised to End Week HigherMay 17, 2023 | msn.comPharma Stocks Weigh Down European Equities in Wednesday TradingMay 16, 2023 | finance.yahoo.comMonthly information related to total number of voting rights and shares composing the share capital _May 15, 2023May 16, 2023 | msn.comPharma Stocks, Vodafone Lead European Equities Lower in Tuesday TradingSee More Headlines Receive ERYP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ERYTECH Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ERYP CUSIPN/A CIK1624422 Webwww.erytech.com Phone(347) 874-4438Fax33-4-78-75-56-29Employees49Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.32 Current Ratio3.65 Quick Ratio3.65 Sales & Book Value Annual Sales$32.66 million Price / Sales3.24 Cash FlowN/A Price / Cash FlowN/A Book Value$0.80 per share Price / Book3.88Miscellaneous Outstanding Shares34,120,000Free Float33,458,000Market Cap$105.77 million OptionableNot Optionable Beta2.69 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Gil Beyen M.B.A. (Age 61)CEO & Director Comp: $624.52kMr. Eric Soyer Ph.D. (Age 57)Deputy GM, CFO & COO Comp: $414.28kDr. Jérôme Bailly Pharm.D. (Age 44)Deputy GM of Operations, Chief Quality Officer & Qualified Person Comp: $270.47kNaomi EichenbaumDirector Investor RelationsMs. Anne-Cécile Fumey (Age 48)HR Director Dr. Iman El-Hariry M.D. (Age 63)Ph.D., Chief Medical Officer Ms. Karine Charton Ph.D.Director of Innovation & ValorizationDr. Philip L. LorenziConsultant & Member of Scientific BoardProf. Eric Raymond M.D.Ph.D., Consultant & Member of Scientific BoardDr. Bridget BaxConsultant & Member of Scientific BoardMore ExecutivesKey Competitorsbluebird bioNASDAQ:BLUEOutlook TherapeuticsNASDAQ:OTLKBioAtlaNASDAQ:BCABaTyr PharmaNASDAQ:LIFEVigil NeuroscienceNASDAQ:VIGLView All Competitors ERYP Stock Analysis - Frequently Asked Questions What other stocks do shareholders of ERYTECH Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other ERYTECH Pharma investors own include Allena Pharmaceuticals (ALNA), Exelixis (EXEL), Madrigal Pharmaceuticals (MDGL), Sesen Bio (SESN), Cidara Therapeutics (CDTX), Fate Therapeutics (FATE), Gilead Sciences (GILD), MEI Pharma (MEIP), Verastem (VSTM) and ACADIA Pharmaceuticals (ACAD). When did ERYTECH Pharma IPO? ERYTECH Pharma (ERYP) raised $125 million in an initial public offering on Friday, November 10th 2017. The company issued 5,300,000 shares at $23.00-$24.00 per share. Jefferies, Cowen and Oddo BHF served as the underwriters for the IPO and JMP Securities was co-manager. This page (NASDAQ:ERYP) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ERYTECH Pharma S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
